(Q34652046)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538710%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

review article

1 reference

title

Immunoglobulin replacement therapy in secondary hypogammaglobulinemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538710%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538710%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Carlo Agostini

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538710%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

author name string

Nicolò Compagno

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538710%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Giacomo Malipiero

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538710%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

publication date

8 December 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538710%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

published in

Frontiers in Immunology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538710%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538710%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

page(s)

626

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538710%20AND%20SRC:MED&resulttype=core&format=json

Rituximab and immune deficiency: case series and review of the literature.

26 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Antibody deficiency secondary to chronic lymphocytic leukemia: Should patients be treated with prophylactic replacement immunoglobulin?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with Rituximab

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Anti-CD20 monoclonal antibodies: beyond B-cells

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Guidelines for supportive care in multiple myeloma 2011.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Immunomodulatory effects of intravenous immunoglobulins (IVIGs) in HIV-1 disease: a systematic review.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Does rituximab increase the incidence of infectious complications? A narrative review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Does rituximab aggravate pre-existing hypogammaglobulinaemia?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Intravenous gammaglobulin treatment in HIV-1 infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Subcutaneous administration of IgG.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Guidelines on the use of intravenous immune globulin for hematologic conditions

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Immune defects in patients with chronic lymphocytic leukemia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Infectious complications in chronic lymphoid malignancy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Mechanisms of polyclonal hypogammaglobulinaemia in multiple myeloma (MM).

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia

7 July 2018

1 reference

https://api.crossref.org/works/10.3389%2FFIMMU.2014.00626

Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFIMMU.2014.00626

Supportive care in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFIMMU.2014.00626

Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFIMMU.2014.00626

Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFIMMU.2014.00626

Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFIMMU.2014.00626

Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFIMMU.2014.00626

Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFIMMU.2014.00626

Risk factors for infection in haematology patients treated with rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFIMMU.2014.00626

FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFIMMU.2014.00626

High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFIMMU.2014.00626

Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFIMMU.2014.00626

Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFIMMU.2014.00626

Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFIMMU.2014.00626

Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFIMMU.2014.00626

Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFIMMU.2014.00626

Subcutaneous IgG replacement therapy is safe and well tolerated in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFIMMU.2014.00626

Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFIMMU.2014.00626

Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFIMMU.2014.00626

Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFIMMU.2014.00626

Intravenous immunoglobulin replacement therapy to prevent pulmonary infection in a patient with Good's syndrome.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Immunological disturbances in Good's syndrome

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4259107

Restoration of humoral immunity after intravenous immunoglobulin replacement therapy in heart recipients with post-transplant antibody deficiency and severe infections

26 October 2018

1 reference

https://api.crossref.org/works/10.3389%2FFIMMU.2014.00626

Risk factors for hypogammaglobulinemia after allo-SCT

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFIMMU.2014.00626

Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia

21 January 2018

1 reference

12 December 2020

Subcutaneous IgG replacement after pediatric SCT

1 reference

12 December 2020

1 reference

12 December 2020

The effect of immunoglobulinVH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics

1 reference

12 December 2020

Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma

1 reference

12 December 2020

Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia

1 reference

12 December 2020

Complicated pathophysiology behind rituximab-induced persistent hypogammaglobulinemia

1 reference

12 December 2020

Safety and infectious prophylaxis of intravenous immunoglobulin in elderly patients with membranous nephropathy

1 reference

12 December 2020

Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study

1 reference

12 December 2020

Efficacy and safety of subcutaneous vivaglobin® replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study

1 reference

12 December 2020

Hypogammaglobulinemia after heart transplantation: impact of pre-emptive use of immunoglobulin replacement (CytoGam) on infection and rejection outcomes

1 reference

12 December 2020

Identifiers

DOI

10.3389/FIMMU.2014.00626

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538710%20AND%20SRC:MED&resulttype=core&format=json

release_vbp2sikq3ncatpcixd44eabmau

26 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vbp2sikq3ncatpcixd44eabmau

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538710%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538710%20AND%20SRC:MED&resulttype=core&format=json